share_log

Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results

Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results

Aytu BioPharma公佈2024財年第三季度運營和財務業績
Accesswire ·  05/16 04:05

Q3 2024 ADHD Portfolio net revenue up 49% compared to Q3 2023

2024 年第三季度注意力缺陷多動症投資組合淨收入與 2023 年第三季度相比增長了 49%

Q3 2024 adjusted EBITDA 1 improved by $7.0 million compared to Q3 2023

2024年第三季度調整後的息稅折舊攤銷前利潤 1 與 2023 年第三季度相比增長了 700 萬美元

TTM March 2024 operating income of $7.3 million for the Rx Business

TTM 2024 年 3 月 Rx 業務的營業收入爲 730 萬美元

TTM March 2024 companywide adjusted EBITDA of positive $15.4 million

TTM 2024 年 3 月全公司調整後的息稅折舊攤銷前利潤爲正1,540萬美元

TTM March 2024 adjusted EBITDA of positive $17.1 million for the Rx Business

TTM 2024 年 3 月 Rx 業務調整後的息稅折舊攤銷前利潤爲正1,710萬美元

$19.8 million cash balance at March 31, 2024

截至 2024 年 3 月 31 日,現金餘額爲 1,980 萬美元

Company to host conference call and webcast today, May 15, 2024, at 4:30 p.m. Eastern time

公司將於今天,即2024年5月15日美國東部時間下午 4:30 舉辦電話會議和網絡直播

DENVER, CO / ACCESSWIRE / May 15, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results for the fiscal 2024 third quarter.

科羅拉多州丹佛/ACCESSWIRE/2024年5月15日/專注於新療法商業化的製藥公司Aytu BioPharma, Inc.(“公司” 或 “Aytu”)(納斯達克股票代碼:AYTU)今天公佈了2024財年第三季度的財務和經營業績。

Q3 2024 Highlights

2024 年第三季度亮點

  • Consolidated net revenue was $18.0 million versus $22.7 million in the prior year period and reflects the Company's continued planned wind down of its Consumer Health Segment.
  • ADHD Portfolio (Adzenys XR-ODT and Cotempla XR-ODT) net revenue increased 49% to $12.3 million versus $8.3 million in Q3 fiscal 2023.
  • Consumer Health Segment net revenue during Q3 2024 was $4.0 million, a decrease of 56% versus Q3 2023, in line with the Company's strategy to discontinue the Consumer Health segment in mid-calendar 2024. As previously announced, the Company is ending its Consumer Health Segment's operations with the objective of driving profitability and generating long-term stockholder value.
  • Rx Segment gross margin improved to 74% in Q3 2024 compared to 61% in Q3 2023.
  • Net loss during Q3 2024 was $2.9 million, or $0.52 per share, compared to a net loss of $7.2 million, or $1.93 per share, in Q3 2023.
  • Consolidated adjusted EBITDA was positive $0.4 million in Q3 2024 compared to negative $6.6 million in Q3 2023.
  • Cash and cash equivalents were $19.8 million at March 31, 2023, compared to $19.5 million at December 31, 2023.
  • 合併淨收入爲1,800萬美元,去年同期爲2,270萬美元,這反映了公司繼續計劃關閉其消費者健康板塊。
  • 注意力缺陷多動障礙投資組合(Adzenys XR-ODT和Cotempla XR-ODT)的淨收入從2023財年第三季度的830萬美元增長了49%,至1,230萬美元。
  • 2024年第三季度消費者健康板塊的淨收入爲400萬美元,與2023年第三季度相比下降了56%,這符合該公司在2024年中期停止消費者健康板塊的戰略。正如先前宣佈的那樣,該公司將結束其消費者健康板塊的業務,目標是提高盈利能力並創造長期股東價值。
  • 與2023年第三季度的61%相比,Rx分部的毛利率在2024年第三季度提高至74%。
  • 2024年第三季度的淨虧損爲290萬美元,合每股虧損0.52美元,而2023年第三季度的淨虧損爲720萬美元,合每股虧損1.93美元。
  • 2024年第三季度合併調整後的息稅折舊攤銷前利潤爲正40萬美元,而2023年第三季度爲負660萬美元。
  • 截至2023年3月31日,現金及現金等價物爲1,980萬美元,而截至2023年12月31日爲1,950萬美元。

Management Discussion

管理層討論

"The positive operating momentum we have experienced over the past two years continued during the third quarter of fiscal 2024, as ADHD Portfolio revenue continued its rapid growth, increasing 49%, and we improved our adjusted EBITDA by $7.0 million, compared to the year ago third quarter. This represents the first March quarter in the company's history during which Aytu generated positive adjusted EBITDA, which is notable considering the March quarter is typically our lowest revenue quarter for the Rx Segment due largely to patients' insurance deductible resets. Further, when considering both the current softness of our pediatric product sales coupled with the well-publicized cyberattack that impacted the entire healthcare industry, we are very encouraged by the Rx Segment's demonstrated, year over year revenue growth." commented Josh Disbrow, Chief Executive Officer of Aytu. "Our business is better positioned today than at any point in our history. Aytu generated TTM adjusted EBITDA of $15.4 million, while our balance sheet remains strong with $19.8 million of cash at the end of March 2024."

“我們在過去兩年中經歷的積極經營勢頭在2024財年第三季度得以延續,與去年同期第三季度相比,ADHD投資組合收入繼續快速增長,增長了49%,調整後的息稅折舊攤銷前利潤增加了700萬美元。這是該公司歷史上第一個3月的季度,在此期間,Aytu調整後的息稅折舊攤銷前利潤爲正。考慮到3月季度通常是我們Rx板塊收入最低的季度,這在很大程度上是由於患者的保險免賠額重置。此外,考慮到我們目前兒科產品銷售疲軟,再加上影響整個醫療行業的廣爲人知的網絡攻擊,我們對Rx細分市場的收入同比增長感到非常鼓舞。” Aytu首席執行官喬什·迪斯布魯評論道。“我們今天的業務比我們歷史上的任何時候都處於更有利的地位。Aytu的TTM調整後息稅折舊攤銷前利潤爲1,540萬美元,而我們的資產負債表仍然強勁,截至2024年3月底,現金爲1,980萬美元。”

"The key drivers to achieving these critical milestones of positive $15.4 million in TTM companywide adjusted EBITDA and positive $17.1 million in Rx Business TTM adjusted EBITDA, have been a combination of redefining our corporate strategic mandate to focus our business solely on the Rx Segment while instituting a number of operational improvements. These improvements include strong sales force execution, the leveraging of our innovative Aytu RxConnect platform, and continued effective expense management. Additionally, once we have fully transitioned manufacturing of our ADHD brands out of our Grand Prairie, Texas facility, we expect to gain additional expense and margin improvements beyond what we're currently generating. While there is still work to be done to mitigate the negative impact of the payor changes within our Pediatric Portfolio, which we believe we will be successful in addressing, we are excited about the overall trajectory of the business as we finish fiscal 2024," Mr. Disbrow concluded.

“實現TTM全公司調整後的息稅折舊攤銷前利潤爲正1,540萬澳元和Rx Business TTM調整後的息稅折舊攤銷前利潤爲正1,710萬美元這些關鍵里程碑的關鍵驅動因素是重新定義了我們的企業戰略使命,將業務僅集中在Rx細分市場,同時進行了多項運營改進。這些改進包括強大的銷售隊伍執行力、利用我們創新的Aytu RxConnect平台以及持續有效的費用管理。此外,一旦我們將ADHD品牌的生產完全移出德克薩斯州大草原的工廠,我們預計將在目前的收入基礎上獲得額外的支出和利潤率提高。儘管在減輕兒科投資組合中付款人變動的負面影響方面仍有工作要做,我們相信我們將成功解決這個問題,但在2024財年結束之際,我們對業務的整體發展軌跡感到興奮,” 迪斯布魯先生總結道。

Non-Core Business Update

非核心業務最新動態

In June 2023, the Company announced that it had instituted a strategic mandate focusing its business solely on its Rx Segment, in an effort to drive long-term stockholder value. The Company has generated positive adjusted EBITDA for fiscal 2023 and for seven of the last reported eight quarters for Rx, excluding the Consumer Health Segment and pipeline R&D (the "Rx Business"). This concentration on the Rx Segment will result in discontinuing the Consumer Health Segment altogether.

2023年6月,該公司宣佈已制定一項戰略任務,將業務僅集中在Rx板塊上,以提高長期股東價值。該公司2023財年的調整後息稅折舊攤銷前利潤爲正,在最近公佈的八個季度中,有七個季度的調整後息稅折舊攤銷前利潤爲正,不包括消費者健康板塊和管道研發(“Rx業務”)。這種對Rx細分市場的專注將導致消費者健康板塊完全停產。

This goal of emphasizing profitability was initially started with the indefinite suspension of all pipeline clinical development programs announced in October 2022 to minimize research and development expense until such time that the Company can fund those efforts with internally generated cash flows or through partnerships. During fiscal 2023, the Consumer Health Segment contributed adjusted EBITDA of negative $3.6 million and pipeline programs contributed adjusted EBITDA of negative $2.6 million, while the Company's Rx Business contributed adjusted EBITDA of positive $9.7 million. Over the Trailing Twelve-Month ("TTM") period ending March 31, 2024, the Company's Rx Business contributed operating income of $7.3 million and adjusted EBITDA of positive $17.1 million.

這一強調盈利能力的目標最初始於2022年10月宣佈無限期暫停所有管道臨床開發計劃,以最大限度地減少研發費用,直到公司能夠通過內部產生的現金流或通過合作伙伴關係爲這些工作提供資金。在2023財年,消費者健康板塊貢獻的調整後息稅折舊攤銷前利潤爲負360萬美元,管道項目的調整後息稅折舊攤銷前利潤爲負260萬美元,而該公司的Rx業務貢獻的調整後息稅折舊攤銷前利潤爲正970萬美元。在截至2024年3月31日的過去十二個月(“TTM”)期間,該公司的Rx業務貢獻了730萬美元的營業收入,調整後的息稅折舊攤銷前利潤爲正1710萬美元。

Segment Reporting

分部報告

Three Months Ended
March 31,
2024 2023
(in thousands)
Consolidated net revenue:
Rx Segment
$ 14,025 $ 13,805
Consumer Health Segment
3,968 8,928
Total consolidated net revenue
$ 17,993 $ 22,733
Rx Segment net revenue:
ADHD Portfolio
$ 12,326 $ 8,272
Pediatric Portfolio
1,729 5,266
Other*
(30) 267
Total Rx Segment net revenue
$ 14,025 $ 13,805
三個月已結束
3月31日
2024 2023
(以千計)
合併淨收入:
Rx 分段
$ 14,025 $ 13,805
消費者健康板塊
3,968 8,928
合併淨收入總額
$ 17,993 $ 22,733
Rx 分部淨收入:
多動症投資組合
$ 12,326 $ 8,272
兒科投資組合
1,729 5,266
其他*
(30) 267
Rx 分部總淨收入
$ 14,025 $ 13,805

_______________

_____________

*Other includes discontinued or deprioritized products.

*其他包括已停產或取消優先次序的產品。

Q3 2024 Financial Results

2024 年第三季度財務業績

Net revenue for the third quarter of fiscal 2024 was $18.0 million, compared to $22.7 million for the prior year period.

2024財年第三季度的淨收入爲1,800萬美元,而去年同期爲2,270萬美元。

Net revenue from the Rx Segment in the third quarter of fiscal 2024 was $14.0 million compared to $13.8 million in the prior year period. The ADHD Portfolio (Adzenys XR-ODT and Cotempla XR-ODT) experienced a 49% increase in net revenue to $12.3 million in the third quarter of fiscal 2024, compared to the prior year period. The Pediatric Portfolio (Poly-Vi-Flor, Tri-Vi-Flor, and Karbinal ER) net revenue decreased to $1.7 million due to customer ordering timing as a result of payor changes that impacted scripts.

2024財年第三季度Rx板塊的淨收入爲1,400萬美元,而去年同期爲1,380萬美元。與去年同期相比,ADHD投資組合(Adzenys XR-ODT和Cotempla XR-ODT)在2024財年第三季度的淨收入增長了49%,達到1,230萬美元。兒科投資組合(Poly-Vi-Flor、Tri-Vi-Flor和Karbinal ER)的淨收入降至170萬美元,這是由於付款人變更影響了腳本,客戶訂購時機。

Net revenue from the Consumer Health Segment was $4.0 million in the third quarter of fiscal 2024, a decrease of 56% over the same quarter last year. As previously announced, the Company is winding down its Consumer Health Segment with the objective of discontinuing this segment to improve operating cash flows to drive long-term stockholder value.

2024財年第三季度消費者健康板塊的淨收入爲400萬美元,比去年同期下降56%。正如先前宣佈的那樣,該公司正在結束其消費者健康板塊,目標是終止該板塊,以改善運營現金流以提高長期股東價值。

Consolidated gross profit was $11.7 million, or 65% of net revenue, in the third quarter of fiscal 2024, compared to $12.7 million, or 56% of net revenue, in the same quarter last year. Gross profit margin for the Rx Segment was 74% in the third quarter of fiscal 2024, compared with 61% in the prior year period.

2024財年第三季度的合併毛利爲1170萬美元,佔淨收入的65%,而去年同期爲1,270萬美元,佔淨收入的56%。2024財年第三季度,Rx板塊的毛利率爲74%,而去年同期爲61%。

Operating expenses, excluding amortization of intangible assets, restructurings costs, and gain from contingent consideration, were $12.6 million in the third quarter of fiscal 2024 compared to $20.8 million in the prior year period. The decrease was a result of reduced Consumer Health spending and improved operational efficiencies.

2024財年第三季度的運營支出,不包括無形資產攤銷、重組成本和或有對價收益,爲1,260萬美元,而去年同期爲2,080萬美元。下降是消費者健康支出減少和運營效率提高的結果。

Loss from operations during the third quarter of fiscal 2024 was $2.5 million compared to $8.6 million in the prior year period.

2024財年第三季度的運營虧損爲250萬美元,而去年同期爲860萬美元。

Net loss during the third quarter of fiscal 2024 was $2.9 million, or $0.52 per share, compared to a $7.2 million net loss, or $1.93 per share, in the prior year period. The fiscal 2024 third quarter results were impacted by $0.2 million of costs associated with the previously announced winding down of the manufacturing facility.

2024財年第三季度的淨虧損爲290萬美元,合每股虧損0.52美元,而去年同期的淨虧損爲720萬美元,合每股虧損1.93美元。2024財年第三季度業績受到與先前宣佈的關閉製造工廠相關的20萬美元成本的影響。

Adjusted EBITDA was positive $0.4 million in the third quarter of fiscal 2024, compared to negative $6.5 million in the prior year period, a $7.0 million improvement. Adjusted EBITDA for the Rx Business was positive $0.9 million in the third quarter of fiscal 2024, compared to negative $4.7 million in the prior year period, a $5.6 million improvement.

2024財年第三季度調整後的息稅折舊攤銷前利潤爲正40萬美元,而去年同期爲負650萬美元,增長700萬美元。2024財年第三季度Rx業務調整後的息稅折舊攤銷前利潤爲正90萬美元,而去年同期爲負470萬美元,增長了560萬美元。

Cash and cash equivalents at March 31, 2023, were $19.8 million compared to $19.5 million at December 31, 2023.

截至2023年3月31日,現金及現金等價物爲1,980萬美元,而截至2023年12月31日爲1,950萬美元。

Conference Call Details

電話會議詳情

Date and Time: Wednesday, May 15, 2024, at 4:30 p.m. Eastern time.

日期和時間: 美國東部時間 2024 年 5 月 15 日星期三下午 4:30。

Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for U.S. callers or +1 (973) 528-0011 for international callers and using the participant access code 300411.

電話信息: 有興趣的人士可以通過撥打(888)506-0062(對於美國來電者)或撥打+1(973)528-0011(對於國際來電者),並使用參與者接入碼300411來參加電話會議。

Webcast Information: The webcast will be accessible live and archived at , and accessible on the Investors section of the Company's website at under Events & Presentations.

網絡直播信息: 該網絡直播將在公司網站的 “投資者” 部分的 “活動與演示” 下方進行直播和存檔。

Replay: A teleconference replay of the call will be available until May 29, 2024 at (877) 481-4010 for U.S. callers or +1 (919) 882-2331 for international callers and using replay access code 50379.

重播: 該電話會議的電話會議重播將持續到2024年5月29日,美國來電者的電話會議電話會議重播電話是(877)481-4010,國際來電者的電話會議重播時間爲+1(919)882-2331,使用重播接入代碼50379。

About Aytu BioPharma, Inc.

關於 Aytu BioPharma, Inc.

Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.

Aytu是一家專注於將新療法商業化的製藥公司。該公司的處方產品包括Adzenys XR-ODT(苯丙胺)緩釋口服崩解片劑(參見完整處方信息,包括盒裝警告)和用於治療注意力缺陷多動障礙(ADHD)的Cotempla XR-ODT(哌醋甲酯)緩釋口服崩解片劑(參見完整處方信息,包括盒裝警告)、Karbinal ER(馬來酸卡比諾沙明),一種延長型Karbinal ER(馬來酸卡賓沙明)釋放抗組胺懸浮液用於治療多種過敏性疾病,以及兩種 Poly-Vi-Flor 和 Tri-Vi-Flor 和 Tri-Vi-Flor基於氟化物的補充性處方維生素產品系列,有多種配方,適用於氟化物缺乏症的嬰兒和兒童。要了解更多信息,請訪問 aytubio.com。

Forward-Looking Statements

前瞻性陳述

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act"). All statements other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as "may," "will," "should," "forecast," "could," "expect," "suggest," "believe," "estimate," "continue," "anticipate," "intend," "plan," or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. These statements are predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others, risks associated with: the Company's plans relating to the Company's ability to efficiently wind down the Consumer Health Segment, the Company's ability to complete the manufacturing transfer of Adzenys XR-ODT and Cotempla XR-ODT, the Company's overall financial and operational performance, potential adverse changes to the Company's financial position or our business, the results of operations, strategy and plans, changes in capital markets and the ability of the Company to finance operations in the manner expected, risks relating to gaining market acceptance of our products, our partners performing their required activities, our anticipated future cash position, regulatory and compliance challenges and future events under current and potential future collaborations. We also refer you to (i) the risks described in "Risk Factors" in Part I, Item 1A of our most recent Annual Report on Form 10‐K and in the other reports and documents it files with the Securities and Exchange Commission.

本新聞稿包括經修訂的1933年《證券法》(“證券法”)第27A條和經修訂的1934年《證券交易法》(“交易法”)第21E條所指的前瞻性陳述。除本新聞稿中包含的歷史事實陳述外,所有陳述均爲前瞻性陳述。前瞻性陳述通常以將來時態書寫和/或前面有 “可能”、“將”、“應該”、“預測”、“可能”、“期望”、“建議”、“相信”、“估計”、“繼續”、“預期”、“打算” 或類似詞語,或此類術語的否定詞或此類術語或類似術語的其他變體。除本演示文稿中包含的歷史事實陳述外,所有陳述均爲前瞻性陳述。這些陳述是預測,受風險和不確定性的影響,可能導致實際事件或結果出現重大差異。除其他外,這些風險和不確定性包括與以下相關的風險:公司與公司有效關閉消費者健康板塊的能力有關的計劃、公司完成Adzenys XR-ODT和Cotempla XR-ODT的生產轉移的能力、公司的整體財務和運營業績、公司財務狀況或業務的潛在不利變化、經營結果、戰略和計劃的變化、資本市場的變化以及公司以這種方式爲運營融資的能力預期、與我們的產品獲得市場認可相關的風險、我們的合作伙伴開展所需活動、我們預期的未來現金狀況、監管和合規挑戰以及當前和未來潛在合作下的未來事件。我們還請您參閱(i)我們最新的10-K表年度報告第一部分第1A項中的 “風險因素” 及其向美國證券交易委員會提交的其他報告和文件中描述的風險。

Footnote 1

腳註 1

Aytu uses the term adjusted EBITDA, which is a term not defined under United States generally accepted accounting principles ("U.S. GAAP"). The Company uses this term because it is a widely accepted financial indicator utilized to analyze and compare companies on the basis of operating performance. The Company believes that presenting adjusted EBITDA by certain categories allows investors to evaluate the various performance of these categories. The Company's method of computation of adjusted EBITDA may or may not be comparable to other similarly titled measures used by other companies. We believe that net income (loss) is the performance measure calculated and presented in accordance with U.S. GAAP that is most directly comparable to adjusted EBITDA. See below for a reconciliation of net income (loss) to adjusted EBITDA.

Aytu使用調整後息稅折舊攤銷前利潤一詞,該術語未在美國公認會計原則(“美國公認會計原則”)中定義。公司之所以使用這個術語,是因爲它是一種被廣泛接受的財務指標,用於根據經營業績分析和比較公司。該公司認爲,按某些類別列出調整後的息稅折舊攤銷前利潤可以讓投資者評估這些類別的各種表現。公司計算調整後息稅折舊攤銷前利潤的方法可能與其他公司使用的其他類似標題的指標相似,也可能不相似。我們認爲,淨收益(虧損)是根據美國公認會計原則計算和列報的績效指標,與調整後的息稅折舊攤銷前利潤最直接相似。淨收益(虧損)與調整後息稅折舊攤銷前利潤的對賬情況見下文。

Contacts for Investors

投資者聯繫方式

Mark Oki, Chief Financial Officer
Aytu BioPharma, Inc.
moki@aytubio.com

馬克·奧基,首席財務官
Aytu BioPharma, Inc.
moki@aytubio.com

Robert Blum or Roger Weiss
Lytham Partners
aytu@lythampartners.com

羅伯特·布魯姆或羅傑·魏斯
萊瑟姆合作伙伴
aytu@lythampartners.com

Aytu BioPharma, Inc.
Unaudited Consolidated Statements of Operations
(in thousands, except per share data)

Aytu BioPharma, Inc.
未經審計的合併運營報表
(以千計,每股數據除外)

Three Months Ended
March 31,
2024 2023
Net revenue
$ 17,993 $ 22,733
Cost of sales
6,300 9,990
Gross profit
11,693 12,743
Operating expenses:
Selling and marketing
6,549 12,804
General and administrative
5,442 7,177
Research and development
619 856
Amortization of intangible assets
1,303 1,198
Restructuring costs
244 -
Gain from contingent consideration
- (734)
Total operating expenses
14,157 21,301
Loss from operations
(2,464) (8,558)
Other expense, net
(1,195) (1,215)
Gain on derivative warrant liabilities
1,017 2,573
Loss before income tax
(2,642) (7,200)
Income tax expense
(245) -
Net loss
$ (2,887) $ (7,200)
Basic and diluted weighted-average common shares outstanding
5,533,555 3,726,779
Basic and diluted net loss per common share
$ (0.52) $ (1.93)
三個月已結束
3月31日
2024 2023
淨收入
$ 17,993 $ 22,733
銷售成本
6,300 9,990
毛利
11,693 12,743
運營費用:
銷售和營銷
6,549 12,804
一般和行政
5,442 7,177
研究和開發
619 856
無形資產的攤銷
1,303 1,198
重組成本
244 -
或有對價的收益
- (734)
運營費用總額
14,157 21,301
運營損失
(2,464) (8,558)
其他費用,淨額
(1,195) (1,215)
衍生權證負債的收益
1,017 2,573
所得稅前虧損
(2,642) (7,200)
所得稅支出
(245) -
淨虧損
$ (2,887) $ (7,200)
已發行基本普通股和攤薄後的加權平均普通股
5,533,555 3,726,779
普通股每股基本虧損和攤薄後淨虧損
$ (0.52) $ (1.93)

Aytu BioPharma, Inc.
Unaudited Consolidated Balance Sheets
(in thousands, except share data)

Aytu BioPharma, Inc.
未經審計的合併資產負債表
(以千計,共享數據除外)

March 31, June 30,
2024 2023
ASSETS
Current assets:
Cash and cash equivalents
$ 19,760 $ 22,985
Accounts receivable, net
29,925 28,937
Inventories
13,193 11,995
Prepaid expenses
7,249 8,047
Other current assets
1,003 868
Total current assets
71,130 72,832
Non-current assets:
Property and equipment, net
967 1,815
Operating lease right-of-use assets
1,795 2,054
Intangible assets, net
54,082 58,970
Other non-current assets
889 792
Total non-current assets
57,733 63,631
Total assets
$ 128,863 $ 136,463
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
$ 10,475 $ 13,478
Accrued liabilities
44,091 46,799
Short-term line of credit
1,581 1,563
Current portion of debt
15,135 85
Current portion of derivative warrant liabilities
3,261 -
Other current liabilities
9,146 7,090
Total current liabilities
83,689 69,015
Non-current liabilities:
Debt, net of current portion
- 14,713
Derivative warrant liabilities
8,609 6,403
Other non-current liabilities
5,788 6,975
Total non-current liabilities
14,397 28,091
Stockholders' equity:
Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding
- -
Common stock, par value $.0001; 200,000,000 shares authorized; 5,567,909 and 5,517,174 shares issued and outstanding, respectively
1 1
Additional paid-in capital
346,132 343,485
Accumulated deficit
(315,356) (304,129)
Total stockholders' equity
30,777 39,357
Total liabilities and stockholders' equity
$ 128,863 $ 136,463
3月31日 6月30日
2024 2023
資產
流動資產:
現金和現金等價物
$ 19,760 $ 22,985
應收賬款,淨額
29,925 28,937
庫存
13,193 11,995
預付費用
7,249 8,047
其他流動資產
1,003 868
流動資產總額
71,130 72,832
非流動資產:
財產和設備,淨額
967 1,815
經營租賃使用權資產
1,795 2,054
無形資產,淨額
54,082 58,970
其他非流動資產
889 792
非流動資產總額
57,733 63,631
總資產
$ 128,863 $ 136,463
負債和股東權益
流動負債:
應付賬款
$ 10,475 $ 13,478
應計負債
44,091 46,799
短期信貸額度
1,581 1,563
債務的流動部分
15,135 85
衍生權證負債的流動部分
3,261 -
其他流動負債
9,146 7,090
流動負債總額
83,689 69,015
非流動負債:
債務,扣除流動部分
- 14,713
衍生權證負債
8,609 6,403
其他非流動負債
5,788 6,975
非流動負債總額
14,397 28,091
股東權益:
優先股,面值0.0001美元;已授權5000萬股;未發行或流通股票
- -
普通股,面值0.0001美元;已授權2億股;已發行和流通的股票分別爲5,567,909和5,517,174股
1 1
額外的實收資本
346,132 343,485
累計赤字
(315,356) (304,129)
股東權益總額
30,777 39,357
負債和股東權益總額
$ 128,863 $ 136,463

Aytu BioPharma, Inc.
Unaudited Reconciliation of Net Loss to Adjusted EBITDA
(in thousands)

Aytu BioPharma, Inc.
未經審計的淨虧損與調整後息稅折舊攤銷前利潤的對賬
(以千計)

For the Three Months Ended March 31, 2024
Rx
Business
Consumer
Health
Pipeline
R&D
Consolidated
Net loss - GAAP
$ (1,876) $ (875) $ (136) $ (2,887)
Depreciation and amortization
1,449 385 - 1,834
Stock-based compensation expense
699 112 - 811
Other expense, net
1,187 8 - 1,195
Gain on derivative warrant liabilities
(1,017) - - (1,017)
Income tax expense
245 - - 245
Restructuring costs
244 - - 244
Adjusted EBITDA - non-GAAP
$ 931 $ (370) $ (136) $ 425
截至2024年3月31日的三個月
Rx
商業
消費者
健康
管道
研發
合併
淨虧損——GAAP
$ (1,876) $ (875) $ (136) $ (2,887)
折舊和攤銷
1,449 385 - 1,834
股票薪酬支出
699 112 - 811
其他費用,淨額
1,187 8 - 1,195
衍生權證負債的收益
(1,017) - - (1,017)
所得稅支出
245 - - 245
重組成本
244 - - 244
調整後的息稅折舊攤銷前利潤-非公認會計准則
$ 931 $ (370) $ (136) $ 425
For the Three Months Ended March 31, 2023
Rx
Business
Consumer
Health
Pipeline
R&D
Consolidated
Net loss - GAAP
$ (5,376) $ (1,423) $ (401) $ (7,200)
Depreciation and amortization
1,563 280 - 1,843
Stock-based compensation expense
788 114 13 915
Gain from contingent consideration
(345) (389) - (734)
Other expense (income), net
1,229 (14) - 1,215
Gain on derivative warrant liabilities
(2,573) - - (2,573)
Adjusted EBITDA - non-GAAP
$ (4,714) $ (1,432) $ (388) $ (6,534)
在截至2023年3月31日的三個月中
Rx
商業
消費者
健康
管道
研發
合併
淨虧損——GAAP
$ (5,376) $ (1,423) $ (401) $ (7,200)
折舊和攤銷
1,563 280 - 1,843
股票薪酬支出
788 114 13 915
或有對價的收益
(345) (389) - (734)
其他支出(收入),淨額
1,229 (14) - 1,215
衍生權證負債的收益
(2,573) - - (2,573)
調整後的息稅折舊攤銷前利潤-非公認會計准則
$ (4,714) $ (1,432) $ (388) $ (6,534)

Aytu BioPharma, Inc.
Unaudited Reconciliation of Trailing Twelve-Month Net Income (Loss) to Adjusted EBITDA
(in thousands)

Aytu BioPharma, Inc.
過去十二個月淨收益(虧損)與調整後息稅折舊攤銷前利潤的未經審計的對賬
(以千計)

Companywide:
For the Three Months Ended
March 31,
2024
December 31,
2023
September
30, 2023
June 30,
2023
Total TTM
Net loss - GAAP
$ (2,887) $ (220) $ (8,120) $ (2,457) $ (13,684)
Depreciation and amortization
1,834 1,899 1,941 1,836 7,510
Stock-based compensation expense
811 820 930 899 3,460
Other expense, net
1,195 1,179 709 1,252 4,335
(Gain) loss on derivative warrant liabilities
(1,017) 577 5,907 1,374 6,841
Income tax expense
245 828 - - 1,073
Restructuring costs
244 - - - 244
One-time transactions
- - 851 - 851
Gain from contingent consideration
- - - (465) (465)
Impairment expense
- - - 5,224 5,224
Adjusted EBITDA - non-GAAP
$ 425 $ 5,083 $ 2,218 $ 7,663 $ 15,389
Rx Business:
For the Three Months Ended
March 31,
2024
December 31,
2023
September
30, 2023
June 30,
2023
Total TTM
Net (loss) income - GAAP
$ (1,876) $ 667 $ (7,321) $ 3,677 $ (4,853)
Depreciation and amortization
1,449 1,510 1,554 1,562 6,075
Stock-based compensation expense
699 707 725 784 2,915
Other expense, net
1,187 1,170 699 1,205 4,261
(Gain) loss on derivative warrant liabilities
(1,017) 577 5,907 (465) 5,002
Income tax expense
245 828 - - 1,073
Restructuring costs
244 - - - 244
One-time transactions
- - 851 - 851
Loss from contingent consideration
- - - 1,374 1,374
Impairment expense
- - - 130 130
Adjusted EBITDA - non-GAAP
$ 931 $ 5,459 $ 2,415 $ 8,267 $ 17,072
全公司:
在已結束的三個月中
3月31日
2024
十二月 31,
2023
九月
2023 年 30 日
6月30日
2023
TTM 總計
淨虧損——GAAP
$ (2,887) $ (220) $ (8,120) $ (2,457) $ (13,684)
折舊和攤銷
1,834 1,899 1,941 1,836 7,510
股票薪酬支出
811 820 930 899 3,460
其他費用,淨額
1,195 1,179 709 1,252 4,335
衍生權證負債的(收益)虧損
(1,017) 577 5,907 1,374 6,841
所得稅支出
245 828 - - 1,073
重組成本
244 - - - 244
一次性交易
- - 851 - 851
或有對價的收益
- - - (465) (465)
減值支出
- - - 5,224 5,224
調整後的息稅折舊攤銷前利潤-非公認會計准則
$ 425 $ 5,083 $ 2,218 $ 7,663 $ 15,389
Rx 業務:
在已結束的三個月中
3月31日
2024
十二月 31,
2023
九月
2023 年 30 日
6月30日
2023
TTM 總計
淨(虧損)收入——GAAP
$ (1,876) $ 667 $ (7,321) $ 3,677 $ (4,853)
折舊和攤銷
1,449 1,510 1,554 1,562 6,075
股票薪酬支出
699 707 725 784 2,915
其他費用,淨額
1,187 1,170 699 1,205 4,261
衍生權證負債的(收益)虧損
(1,017) 577 5,907 (465) 5,002
所得稅支出
245 828 - - 1,073
重組成本
244 - - - 244
一次性交易
- - 851 - 851
或有對價造成的損失
- - - 1,374 1,374
減值支出
- - - 130 130
調整後的息稅折舊攤銷前利潤-非公認會計准則
$ 931 $ 5,459 $ 2,415 $ 8,267 $ 17,072

SOURCE: Aytu BioPharma, Inc.

來源:Aytu BioPharma, Inc.


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論